Baymatob Operations Pty. Ltd news

Baymatob^TM has celebrated the arrival of their newest member, Baby Alex. Baby Alex is the third child of the company`s CEO, Dr Sarah McDonald, and she has been assisting the Baymatob^TM team since well before her arrival into the world across areas including product development, data collection and user feedback. 

Throughout her pregnancy and labour Sarah wore the latest version of the Oli^TMdevice. In addition to this Sarah

Sydney medical device company Baymatob has completed a placement of $4.215 million, with proceeds used to continue in-human clinical trials for its AI-guided labour monitoring device, Oli.

Cornerstoned by Australian Unity’s Future of Healthcare Fund, the placement was strongly supported by Australian institutional and high net worth investors, securing long-term capital partners to support Baymatob’s ongoing clinical development and path to commercialisation.

Found

Today the Ingham Institute launched their centre for Robotics and Health Technology from the Baymatob^TM premises. The Institute is one of the only in Australia to combine clinical expertise with commercial partnerships to oversee the life cycle of bringing life-saving treatments to market – from concepts to clinical trials to commercialisation and introduction into the healthcare systems. The event was a fantastic success attended by a number of individuals

Baymatob^TM CEO, Sarah McDonald, presented an embedded culture enquiry showcase presentation as part of the 2017 NSW Health Innovation Symposium exploring why it takes so long for health and medical innovations to find their way into everyday practice in the health care system. This presentation gave an overview of the Oli^TM product, her PhD research and emphasised the importance of the greater team to best ensure that needed health and medical innovations

Baymatob^TM, a MedTech company founded by a Sydney mother after her own traumatic birth experience, has developed a world-first labour monitoring device that has achieved US Food and Drug Administration (FDA) Breakthrough Device Designation. This sets Baymatob’s game changing maternal diagnostic tool called Oli^TM on an streamlined and supported path toward regulatory approval.

Oli seeks to identify an individual, during labour, who is at hi